Search - tctmd.com

Displaying 101 - 120 of 355

Sort: Relevancy | Date

News Conference News AHA 2014

Biodegradable-Polymer DES Perform Well But Appear No Safer than Their Durable-Polymer Counterparts

November 18, 2014

News Daily News

SECURITY: 6 Months of DAPT Noninferior to 12 Months in Low-Risk Patients After PCI

Yael L. Maxwell

November 17, 2014

News Daily News

SECURITY: 6 Meses de Terapia Antiplaquetaria Doble No son Inferiores a 12 Meses en Pacientes de Bajo Riesgo Post-PCI

Yael L. Maxwell

November 17, 2014

News Daily News

SECURITY：在PCI后的低风险患者中，6个月DAPT相对于12个月的该策略具有非劣效性

Yael L. Maxwell

November 17, 2014

News Conference News AHA 2014

ITALIC Shows Noninferiority of 6-Month DAPT in Good Aspirin Responders

Yael L. Maxwell

November 15, 2014

News Daily News

研究证实采用较新DES时支架内血栓形成和心肌梗死风险降低

Salynn Boyles

November 02, 2014

News Daily News

Un Estudio Confirma Menor Riesgo de Trombosis del Stent,IM con los Nuevos SLF

Salynn Boyles

November 02, 2014

News Daily News

TWENTE: Second-Generation DES Show Good Long-term Outcomes in Bifurcation Lesions

L.A. McKeown

November 02, 2014

News Daily News

TWENTE: los SLF de 2ª Generación tienen Buenos Resultados a Largo Plazo en Lesiones en Bifurcación

L.A. McKeown

November 02, 2014

News Daily News

TWENTE：第二代DES在分叉病变中表现出良好的长期结果

L.A. McKeown

November 02, 2014

News Daily News

Study Confirms Lower Stent Thrombosis, MI Risks With Newer DES

Salynn Boyles

November 02, 2014

Presentation

Three-Year Clinical Outcome of Patients With Bifurcation Treatment With Second-Generation Resolute and Xience V Stents

Presenter: M.K. Lam

October 31, 2014

Presentation TCT 2014

Clinical Outcomes of Patients With High Risk Acute Coronary Syndrome Treated With a New Generation Drug-Eluting Stent, Ultimaster compared with Xience ? Results from CENTURY II___

Presenter: Kazushige Kadota

September 16, 2014

Presentation TCT 2014

Long-term Clinical Outcomes in Real-World Patients with Acute Myocardial Infarction Receiving XIENCE V® Everolimus-Eluting Stents: Four-Year Results from the XIENCE V USA Study_

Presenter: Krishnankutty Sudhir

September 16, 2014

News Conference News TCT 2014

SECURITY: Six-Month DAPT Noninferior to 12 Months with Second-Generation DES

September 15, 2014

News Conference News TCT 2014

EES Decrease Restenosis, TVR vs. BMS in Non-STEMI

September 15, 2014

News Industry News

Abbott Initiates ABSORB IV Trial to Evaluate Quality of Life and Cost Savings of Dissolving Heart Device

September 15, 2014

News Conference News TCT 2014

RIBS IV: EES Superior to DEB in Patients with In-Stent Restenosis

September 14, 2014

News Conference News TCT 2014

Pooled Trial Data Show No Stent Thrombosis Reduction with Biodegradable Stent

September 14, 2014

News Conference News TCT 2014

COMPARE II: STEMI Patients See Strong Results with Both BES and EES

September 14, 2014

Advertisement

Biodegradable-Polymer DES Perform Well But Appear No Safer than Their Durable-Polymer Counterparts

SECURITY: 6 Months of DAPT Noninferior to 12 Months in Low-Risk Patients After PCI

SECURITY: 6 Meses de Terapia Antiplaquetaria Doble No son Inferiores a 12 Meses en Pacientes de Bajo Riesgo Post-PCI

SECURITY：在PCI后的低风险患者中，6个月DAPT相对于12个月的该策略具有非劣效性

ITALIC Shows Noninferiority of 6-Month DAPT in Good Aspirin Responders

研究证实采用较新DES时支架内血栓形成和心肌梗死风险降低

Un Estudio Confirma Menor Riesgo de Trombosis del Stent,IM con los Nuevos SLF

TWENTE: Second-Generation DES Show Good Long-term Outcomes in Bifurcation Lesions

TWENTE: los SLF de 2ª Generación tienen Buenos Resultados a Largo Plazo en Lesiones en Bifurcación

TWENTE：第二代DES在分叉病变中表现出良好的长期结果

Study Confirms Lower Stent Thrombosis, MI Risks With Newer DES

Three-Year Clinical Outcome of Patients With Bifurcation Treatment With Second-Generation Resolute and Xience V Stents

Clinical Outcomes of Patients With High Risk Acute Coronary Syndrome Treated With a New Generation Drug-Eluting Stent, Ultimaster compared with Xience ? Results from CENTURY II___

Long-term Clinical Outcomes in Real-World Patients with Acute Myocardial Infarction Receiving XIENCE V® Everolimus-Eluting Stents: Four-Year Results from the XIENCE V USA Study_

SECURITY: Six-Month DAPT Noninferior to 12 Months with Second-Generation DES

EES Decrease Restenosis, TVR vs. BMS in Non-STEMI

Abbott Initiates ABSORB IV Trial to Evaluate Quality of Life and Cost Savings of Dissolving Heart Device

RIBS IV: EES Superior to DEB in Patients with In-Stent Restenosis

Pooled Trial Data Show No Stent Thrombosis Reduction with Biodegradable Stent

COMPARE II: STEMI Patients See Strong Results with Both BES and EES

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content